The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Abstract
We have investigated the pharmacologic effects of a new bisphosphonate compound, CGP 42′446 [2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonate], on bone metabolism. The compound exhibited potent inhibitory activity on the bone resorption induced by 1,25-dihydroxyvitamin D3 both in vivo in the thyroparathyroidectomized rat (ED50 0.072 μg/kg SC) and in vitro in mouse calvarial cultures (IC50 0.002 μM). A comparison of the in vivo and in vitro inhibitory potencies of a total of nine bisphosphonates revealed an excellent correlation between the two assays (r = 0.97). CGP 42′446 also potently inhibited calvarial bone resorption induced by parathyroid hormone (1–34), parathyroid hormone-related protein (1–34), and recombinant human interleukin-1β. Short-term treatment of growing rats with CGP 42′446 dose-dependently increased the radiographic density of the tibial proximal metaphysis (ED50 1.7 μg/kg SC) as well as increasing the calcium and hydroxyproline content of femoral trabeculae (ED50 values 0.17 and 1.1 μg/kg SC, respectively), but there was no detectable effect on cortical bone. On a molar basis in this range of in vivo screening assays, CGP 42′446 was between 940-fold (thyroparathyroidectomized rat) and 87-fold (rat femoral trabecular calcium content) more potent than pamidronate. It is concluded that CGP 42′446 is a promising new, highly potent bisphosphonate for the suppression of the increased bone resorption associated with various diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060915 · Cited by 239
Flanagan, A. M., & Chambers, T. J. (1991) · Calcified Tissue International · doi:10.1007/bf02555852 · Cited by 171
Cited by
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Cellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Pathologic fractures correlate with reduced survival in patients with malignant bone disease
Saad, F., Lipton, A., Cook, R., Chen, Y., Smith, M., & Coleman, R. (2007) · Cancer · doi:10.1002/cncr.22991 · Cited by 667
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Metadata
- Authors
- Green, J. R., Müller, K., & Jaeggi, K. A.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-05-01
- Volume
- 9
- Issue
- 5
- Pages
- 745-751
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2074890088
- Cited by
- 415
- References
- 2
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. https://app.cochat.ai/papers/10.1002/jbmr.5650090521
- The paper
- Green, J. R., Müller, K., & Jaeggi, K. A. (1994). Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.5650090521
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.